* Determine clinical characteristics of parkinsonian patients in various stages of disease; * Measure peripheral neurodegeneration, synaptic, and inflammation biomarkers in a population of parkinsonian patients at various stages of disease. * Measure vesicular neurodegeneration, synaptic and inflammation biomarkers
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
200
blood sample
Flavia Torlizzi
Roma, Italy
RECRUITINGDetermine clinical characteristics of parkinsonian patients in various stages of disease
Determine clinical characteristics of parkinsonian patients in various stages of disease by means of MDS-UPDRS score changes.
Time frame: 3 years
Determine clinical characteristics of parkinsonian patients in various stages of disease
Determine clinical characteristics of parkinsonian patients in various stages of disease by means of NMS score changes.
Time frame: 3 years
Determine biooogical characteristics of parkinsonian patients in various stages of disease
dosage of serum IL-1b, IL6, IL-5, IL-4, IL17, TNFa, IFNg, IL10, total-alpha-synuclein, NfL, BDNF (ng/ml for all)
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.